Skip to content

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

Clinical trial: Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet. This trial is entitled Controlled Study of Humira adalimumab in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet. The primary. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet 2Original Study ID: M10-405. NCT ID: NCT00735787. Brief Title: Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet. Cosentyx is approved by the FDA for moderate to severe plaque psoriasis in adults. 404 patients with moderate to severe psoriasis on the hands, feet and nails. The multicenter, randomized, double blind, placebo-controlled study three concentrations of BBI-4000 versus vehicle (placebo gel) in 189 people with primary axillary hyperhidrosis. This randomized, double-blind, placebo-controlled study enrolled 160 patients with chronic pruritus in psoriasis. Idera Pharmaceuticals reported results from a phase II trial of IMO-3100 for the treatment of plaque psoriasis.

Aetna considers biological therapies adalimumab (Humira), apremilast (Otezla), etanercept (Enbrel), infliximab (Remicade), secukinumab (Cosentyx), and ustekinumab (Stelara) medically necessary for adults aged 18 years and older with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy when the following selection criteria are met:. In a randomized, multi-center, double-blind, placebo-controlled clinical study, Strober et al (2009) evaluated the effectiveness of alefacept for the treatment of severe alopecia areata (AA). TRANSFIGURE is the largest (N 198) and longest duration (132-week treatment period) randomized controlled study of a biologic in moderate-to-severe plaque psoriasis with significant nail psoriasis to report results to date. Secukinumab is effective in subjects with moderate to severe palmoplantar psoriasis: 16 week results from the GESTURE study 23rd World Congress of Dermatology. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. ClinicalTrials.gov is a registry of clinical studies conducted primarily within the United States. (last updated: Feb 20, 2016).

Controlled Study Of Humira In Subjects With Chronic Plaque Psoriasis Of The Hands Feet

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet 3Increased levels of TNF are also found in psoriasis plaques. In Ps, treatment with HUMIRA may reduce the epidermal thickness and infiltration of inflammatory cells. In subjects with HS, a dose of 160 mg HUMIRA on Week 0 followed by 80 mg on Week 2 achieved serum adalimumab trough concentrations of approximately 7 to 8 g/mL at Week 2 and Week 4. Radiographs of hands, wrists, and feet were obtained at baseline and Week 24 during the double-blind period when patients were on HUMIRA or placebo and at Week 48 when all patients were on open-label HUMIRA. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects. Psoriasis is a common chronic skin disorder typically characterized by erythematous papules and plaques with a silver scale, although other presentations occur. Psoriasis of the hand, foot, or face can be debilitating functionally or socially and may deserve a more aggressive treatment approach. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.

Psoriasis And Psoriatic Arthritis: Biological Therapies